---
title: "Outlook Therapeutics, Inc. (OTLK.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/OTLK.US/overview.md"
symbol: "OTLK.US"
name: "Outlook Therapeutics, Inc."
parent: "https://longbridge.com/en/quote/OTLK.US.md"
datetime: "2026-04-05T13:11:21.923Z"
locales:
  - [en](https://longbridge.com/en/quote/OTLK.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/OTLK.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/OTLK.US/overview.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/OTLK.US/overview.md) | [繁體中文](https://longbridge.com/zh-HK/quote/OTLK.US/overview.md)


# Outlook Therapeutics, Inc. (OTLK.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Address | 111 S. Wood Avenue, Unit #100, Iselin, New Jersey, United States |
| Website | [outlooktherapeutics.com](https://outlooktherapeutics.com) |

## Company Profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora.

## Key Executives

| Name | Title |
|------|-------|
| Robert Charles Jahr | President, CEO & Director |
| Faisal G. Sukhthian | Independent Chairman of the Board |
| Lawrence A. Kenyon | EVP, CFO, Treasurer, Secretary & Director |
| Joel Prieve | Senior Vice President of Licensing and M&A |
| Surendra Sharma | Senior Vice President of Medical Affairs |
| Jennifer M. Kissner | Senior Vice President of Clinical Development & Regulatory Affairs |
| Kurt J. Hilzinger | Independent Director |
| Ralph H. Thurman | Lead Independent Director |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| GMS Ventures & Investments | 12.95% | 2025-05-27 |
| Schonfeld Strategic Advisors LLC | 2.33% | 2025-12-31 |
| Syntone Technologies Group Co. Ltd. | 1.63% | 2025-01-15 |
| Armistice Capital LLC | 1.53% | 2025-03-28 |
| The Vanguard Group, Inc. | 1.40% | 2025-12-31 |
| BlackRock, Inc. | 0.39% | 2025-12-31 |
| Gilpin Wealth Management LLC | 0.34% | 2025-12-31 |
| Geode Capital Management, LLC | 0.30% | 2025-12-31 |
| Marshall Wace LLP | 0.29% | 2025-12-31 |
| UBS Asset Management AG | 0.20% | 2025-12-31 |

## Business Breakdown

| Segment | Revenue | Ratio |
|---------|---------|-------|
| Biotechnology | 1413535 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Outlook Therapeutics, Inc. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Biotechnology",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## Geographic Segments

| Region | Revenue | Ratio |
|--------|---------|-------|
| United States | 1413535 | 100% |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**